2. Academic Validation
  3. Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma

Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma

  • Ann N Y Acad Sci. 2002 Jun;963:46-52. doi: 10.1111/j.1749-6632.2002.tb04093.x.
L Giannitrapani 1,  M Cervello,  M Soresi,  M Notarbartolo,  M La Rosa,  L Virruso,  N D'Alessandro,  G Montalto
Affiliations

Affiliation

  • 1 Istituto di Medicina Interna e Geriatria, Università di Palermo, Palermo, Italy.
PMID: 12095927 DOI: 10.1111/j.1749-6632.2002.tb04093.x
Abstract

Interleukin-6 plays a central role in regulating the immune system, hematopoiesis, and acute phase reaction. It interacts with a receptor complex consisting of a specific ligand-binding protein (IL-6R, gp80) and a signal transduction protein (gp130). In this report, serum levels of IL-6 and a soluble form of the interleukin-6 receptor (sIL-6R) were evaluated in patients with hepatocellular carcinoma. The correlation between IL-6 and sIL-6R values, the stage of hepatocellular carcinoma, and main liver function tests was also studied.

Figures
Products